United Therapeutics Corporation
NASDAQ•UTHR
CEO: Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
セクター: Healthcare
業種: Biotechnology
上場日: 1999-06-17
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
連絡先情報
時価総額
$23.35B
PER (TTM)
17.7
17.5
配当利回り
--
52週高値
$548.12
52週安値
$266.98
52週レンジ
順位24Top 10.8%
5.7
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 5.7 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$790.20M+0.00%
直近4四半期の推移
EPS
$8.36+0.00%
直近4四半期の推移
フリーCF
$173.30M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Total Revenue Growth Strong Total revenues reached $3.18B USD in 2025, marking an 11% increase over 2024 results.
Net Income Increased Substantially Net income grew to $1.33B USD in 2025, reflecting strong profitability improvement across operations.
Tyvaso DPI Sales Surge Tyvaso DPI net product sales grew 25% to $1.29B USD, driven by increased patient utilization.
Operating Cash Flow Rises Net cash provided by operating activities was $1.56B USD, increasing 18% compared to prior year.
リスク要因
Heavy Product Sales Reliance Treprostinil-based therapies comprise the vast majority of total revenues, posing significant revenue concentration risk.
Generic Competition Pressures Sales Generic versions of Remodulin and Adcirca competition materially impacted prior revenues; future erosion expected.
Ongoing Litigation Financial Exposure Sandoz litigation resulted in a $71.1M liability accrual in 2024; ultimate outcome remains uncertain.
Manufacturing Third-Party Dependency Reliance on third parties for critical manufacturing and supply chain activities exposes operations to disruption risks.
見通し
Pipeline Advancement Key Focus Phase 3 TETON studies for Nebulized Tyvaso in IPF/PPF and ADVANCE OUTCOMES for Ralinepag ongoing.
Capital Investment Planned Budgeted approximately $400M USD through 2028 for constructing new manufacturing facilities supporting growth.
Xenograft Trials Progressing UKidney EXPAND Phase 1/2/3 trial initiated in Q4 2025; UThymoKidney EXTEND IND cleared July 2025.
Significant Share Repurchase Executed Entered 2025 ASR agreements paying $1.0B USD upfront to repurchase common stock through early 2026.
同業比較
売上高 (TTM)
$21.31B
$11.04B
$9.81B
粗利益率 (最新四半期)
100.0%
92.3%
90.9%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| BIIB | $27.14B | 21.0 | 7.3% | 23.6% |
| UTHR | $23.35B | 17.7 | 19.3% | 0.0% |
| DGX | $22.35B | 22.5 | 13.9% | 42.6% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-0.2%
横ばい
4四半期純利益CAGR
4.2%
収益性の緩やかな改善
キャッシュフロー安定性
100%
優れたキャッシュフローの実績
深度リサーチ
次回決算:2026年4月28日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし